drugset / Trial / NCT07226843
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Timeline
- Start
- 2026-04-17
- Primary completion
- 2027-04
- Completion
- 2030-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY4584180 | Unknown | — | Oral |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |